Insider transactions

Srinivas Akkaraju

CIK 1253170 · last filed 2026-09-09

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$182.66M
Companies
22
Total Filings
192
Lifetime Open-Market Net
$181.59M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

SRRK price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
565 EVERETT AVENUE
PALO ALTO, CA 94301
Related Filers
Samsara BioCapital, L.P. — 21 joint filings, latest 2026-05-22
Philippe O. Chambon — 11 joint filings, latest 2013-02-20
James Healy — 11 joint filings, latest 2015-10-13
Vijay K Lathi — 11 joint filings, latest 2013-02-20
James Niedel — 11 joint filings, latest 2013-02-20
Sofinnova Management VIII, L.L.C. — 10 joint filings, latest 2015-10-13
Ronald Hunt — 9 joint filings, latest 2013-02-20
Anand Mehra — 9 joint filings, latest 2015-10-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ALMS Director 4,667,288 $6.34 $29.59M $55.26M 14 2026-09-09
VTVT Director 106,000 $26.51 $2.81M $0 8 2026-06-29
SRRK Director 558,009 $42.48 $23.70M $603.3K 9 2026-06-08
KLRS Director 19,408 $1.81 $35.2K $5.90M 3 2026-06-04
MLYS Director 5,877,218 $20.56 $120.84M $53.10M 8 2026-02-20
Kalaris Therapeutics, Inc. (ALVR) Delisted Director 11,444,503 $9.81 $112.27M $0 1 2025-03-18
Syros Pharmaceuticals, Inc. (SYRS) Delisted Director 1,795,760 $0.00 $718 $7.14M 22 2024-09-18
CARGO Therapeutics, Inc. (CRGX) Delisted 10%+ Owner 4,415,689 $4.47 $19.74M $14.99M 1 2024-06-03
CHINOOK THERAPEUTICS, INC. (KDNY) Delisted Director 0 $40.39 $0 $27.49M 8 2023-08-11
INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted Director 686,686 $19.00 $13.05M $16.76M 33 2023-05-25
LENZ Therapeutics, Inc. (GRPH) Delisted 10%+ Owner 5,393 $22.26 $120.0K $455.1K 1 2021-12-20
Jiya Acquisition Corp. (JYAC) Delisted Director 507,041 $10.04 $5.09M $0 2 2021-08-30
Seagen Inc. (SGEN) Delisted Director 2,183,433 $228.74 $499.44M -$30.51M 36 2020-05-19
Aravive, Inc. (ARAV) Delisted Director 607,881 $0.04 $24.4K $1000.0K 4 2019-12-02
Principia Biopharma Inc. (PRNB) Delisted Director 208,480 — — $2.98M 2 2019-01-10
Aravive, Inc. (VSAR) Delisted Director 474,548 — — $25.70M 12 2018-10-16
LIFE Director 133,295 $42.62 $5.68M $4.48M 5 2017-05-11
SYNLOGIC, INC. (MIRN) Delisted 10%+ Owner 2,974,811 — — $30.00M 1 2015-10-06
ZS Pharma, Inc. (ZSPH) Delisted Director — — — $0 2 2015-06-29
SYNAGEVA BIOPHARMA CORP (GEVA) Delisted Director 1,340,283 — — -$24.74M 4 2012-06-28
PHARMOS CORP (PARS) Delisted Director 14,226 — — $0 4 2009-01-27
BARRIER THERAPEUTICS INC (BTRX) Delisted Director 46,312 — — -$9.01M 2 2007-06-08

Recent Filings · Page 8 of 20

192 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-12-11 Syros Pharmaceuticals, Inc. (SYRS) Delisted Grant (A) +625,000 $0 EDGAR
2020-12-11 Jiya Acquisition Corp. (JYAC) Delisted Grant (A) +14,082 $140.8K EDGAR
2020-10-07 CHINOOK THERAPEUTICS, INC. (KDNY) Delisted Grant (A) +3,168,388 $0 EDGAR
2020-08-19 Syros Pharmaceuticals, Inc. (SYRS) Delisted Sell (S) −159,327 -$2.09M EDGAR
2020-07-06 Syros Pharmaceuticals, Inc. (SYRS) Delisted Sell (S) −4,627 -$51.0K EDGAR
2020-06-25 Syros Pharmaceuticals, Inc. (SYRS) Delisted Sell (S) −154,700 -$1.72M EDGAR
2020-06-11 Syros Pharmaceuticals, Inc. (SYRS) Delisted Grant (A) — $0 EDGAR
2020-06-01 INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted Grant (A) +1,595 $0 EDGAR
2020-05-19 Seagen Inc. (SGEN) Delisted Grant (A) +1,335 $0 EDGAR
2020-05-07 Seagen Inc. (SGEN) Delisted Mixed — -$1.25M EDGAR
Showing 71–80 of 192
Page 8 of 20
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.